Compare GAIN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAIN | CERS |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.5M | 585.1M |
| IPO Year | 2005 | 1996 |
| Metric | GAIN | CERS |
|---|---|---|
| Price | $16.45 | $2.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | 194.7K | ★ 3.0M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | 20.63 | ★ 27.27 |
| EPS | ★ 0.76 | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $9.07 | $19.95 |
| Revenue Next Year | $7.32 | $8.84 |
| P/E Ratio | $21.72 | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $13.14 | $1.17 |
| 52 Week High | $17.14 | $3.47 |
| Indicator | GAIN | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 48.23 |
| Support Level | $15.78 | $2.37 |
| Resistance Level | $17.01 | $2.91 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 44.57 | 57.23 |
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S., to achieve and grow current income by investing in debt securities of established businesses, and to provide stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.